Drug Trial Radar · NCT06388083
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 31, 2024
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Belite Bio, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
Conditions
- STGD1
- Stargardt Disease 1
Interventions
TinlarebantDrug
5 mg tablet
PlaceboDrug
Placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- To measure the annualized rate of change from baseline lesion size in aggregate area of atrophyTime frame: From baseline to Month 24
Locations
18 sites in 3 countries. Site status is shown where the registry gives one.
Belite Study Site - US08
Phoenix, Arizona
Belite Study Site - US05
La Jolla, California
Belite Study Site - US09
San Francisco, California
Belite Study Site - US06
Miami, Florida
Belite Study Site - US01
Boston, Massachusetts
Belite Study Site - US11
Edina, Minnesota
Belite Study Site - US04
Rochester, Minnesota
Belite Study Site - US14
New York, New York
Belite Study Site - US10
Westbury, New York
Belite Study Site - US02
Durham, North Carolina
Belite Study Site - US07
Philadelphia, Pennsylvania
Belite Study Site - US13
Austin, Texas
Belite Study Site - US03
Dallas, Texas
Belite Study Site - US12
The Woodlands, Texas
Belite Study Site
Kobe, Japan
Belite Study Site
Kyoto, Japan
Belite Study Site
Tokyo, Japan
UK01 Belite Study Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.